Dimitri Krainc, MD, PhD currently serves as the Ward Professor and Chairman of the Department of Neurology and Director of the Center for Neurogenetics at Northwestern University, Feinberg School of Medicine in Chicago. Previously, Dr. Krainc spent more than 20 years at Harvard Medical School where he completed his research training followed by a neurology residency and fellowship in movement disorders at Massachusetts General Hospital. He then served on the neurology faculty at MGH and Harvard Medical School until 2013 when he relocated to Chicago. The overarching goal of Dr. Krainc’s research is to study molecular mechanisms of neurodegeneration, focusing on Parkinson’s and Huntington’s disease, to facilitate the development of targeted therapies. In the area of PD, his group identified a positive feedback loop between alpha-synuclein and glucocerebrosidase in sporadic and genetic forms of PD (Mazzulli et al, Cell, 2011). They also described convergence of mitochondrial and lysosomal dysfunction in midbrain neurons from PD patients (Burbulla et al, Science, 2017), as well as direct contacts between lysosomes and mitochondria (Wong et al, Nature, 2018). Dr. Krainc is the principal founder of Lysosomal Therapeutics, Inc. and serves on the SAB of Intellia Therapeutics and Prevail Therapeutics. He received several awards for his work, including the Javits Neuroscience Award.